Well, morning, Good topics our call I'll thanks morning. joining. on for thanks, Tina. this cover three and
a off this First, quarter. where we an are the launch, update strong start Rezdiffra to on
with and Our key metrics consistent to intent awareness are reflecting strength prescribe. also are physician and high market showing research
progress wiring the expect X we what a priority. our be #X we where about our into process. to months XX-month are This system, is Second,
behavior a efficient As launches, first-in-disease we and are processes patient developing in with clinical practice driving physician and prescription other and for change flow.
establish Rezdiffra. Our support peak foundation value of maximize to strong goal sales.
And is to to a long-term third, our the strategy
plan to next Rezdiffra untapped the expected to launch opportunity in that the directly addition we announced Europe In EMA we following U.S., in year. decision an today
on X. Slide Let's the launch start with
uptake. and more the areas: payer second providing X quarter sales million our quarter in are Rezdiffra. patients demand, coverage We than metrics exited patient quarter in $XX.X key first on the net discussed including with As generated in numbers, quarter X,XXX second and prescriber we on call,
fill specialty demand, Madrigal we and lot payers. the prescription it the on time driving of takes pharmacies to community, patient a put support, focus a have to with addition In physician
with selection on focused is team prescribers. patient field Our
Our distribution are specialty efficient pharmacies in the efficiently the limited and patient payers on need. support executing exceptions recognize our driving more are unmet processing they network medical team and prescription because
quickly result, process. moving the through a patients As are more reimbursement
We at about the need coverage transplants about was clinical patients is Rezdiffra NASH, or States. commercial understand They of They second expectation those our months. United payers. fill to or our quarter Because NITs, time of standard lives. unmet the XX liver also the care.
Last improve days for less also quarter encouraged women XX very in are the discussed have recognize efforts, to made in for not time from to launch at to in progress days tests that fill running significant was previously noninvasive for X which with a we've XX% #X compared the and initial biopsies expectations.
We're FX/FX of by faster driver at of the of benefits to
As and of lives, June Rezdiffra biopsies. XX% not than for commercial place covered have requiring in coverage of Rezdiffra of lives more over accepting now XX, with NITs XX%
of commercial XX% covered well to lives of achieving on our year-end. way We by are goal our
biopsies. As far all virtually all commercial in NITs Medicaid July as states. do as XX accept was X, and to with coverage we've government of not coverage payers, seen what place Similar require across
via medications.
Currently, consistent For with requirements authorization process accessing Medicare, annual the we are based process Rezdiffra coverage next review on are X our the label. on Medicare track year exception patients medical for beginning new January full of with for prior
launches penetration XX% diagnosed X,XXX medicines. and of quarter, the prescription, a aligned We have with second we targets is made FX/FX of with hepatologists top that blockbuster approximately are level for caring are the Rezdiffra the vast top which targeting, gastroenterologists we majority often are progress our XXX,XXX pleased in seen wrote who with the the of patients.
In the
you'd the expect, their their bit given Gastroenterology hepatologists in different can primary think the with and launch, activation board, that we NITs. longer physician quickly take to stage disease As each practices area seen dynamics patients.
Across adopting more through expertise early disease a NASH add continue of for due we've a is they need at and and prescribers. to to practice steadily isn't
prescribers. process Our and continue efforts. that do XX-month top conviction new writing of opportunity shift prescribers system targeting wire the on X.
We're XX% to be what that Significant the targets substantially initial expect expand about with Slide the stages physicians to to more prescriptions well, we're To more prescribers to are than to successfully in giving accomplish goal. us this we right we remains as frequent early to need a noted of their
and treatments, with first-time work behavior to to lot there's are Just physicians' change patients the steadily do. states pathway build help Rezdiffra disease like in launch prescriptions made and process of are physician a but it's at We've efficiently we working early prescriber to still adding other great we offices. progress, and a
For risks urgent. they physicians, real the of activating to are and risks a educating them write about are The NASH it's on and prescription.
of years. For progression outcomes. NASH patients XX,XXX liver-related highlights baseline, Optum example, to XX% Of progressed cirrhosis approximately without study database cirrhosis within adverse economic an claims to our health decompensated at X of alarming rates
panel using identify Rezdiffra are U.S. disease the physicians In using as we state published and and guidelines. NITs addition to as appropriate well also helping the recommendations expert recently EASL for Rezdiffra patients education,
staff, patients future staff For to to helping evolving volume create process This pathway it's patients require additional and manage can about handle process. and the to the office the prescriptions practices anticipate. navigate we reimbursement a
continuing NASH, and and on testing paying off That's the coverage. system patients. of to health been their to continue we're have care of noninvasive NASH with different treatment benefits journey. the while through risk And support to the the for favorable clinical patients, navigate For Rezdiffra of payers, helping dialogue them on of complexities them costs we educate productive Rezdiffra
that requires a repetition discipline, time. approach absolutely work, patient-by-patient. tailored So doing This the we're practice-by-practice, and payer-by-payer physician-by-physician, and is
a to pull through wired, to accounts smoother it's the blockbuster As the still more create through. prescriptions early building We're easier confident medicine. that in are but and we become foundation the stages, becomes send process needed we're
launch drives optimism our Rezdiffra as X. of noted our Europe, on The to directly Slide in commercialize decision U.S.
We Europe marketing following have been our year. the submission of earlier application strategy evaluating our this
next which expect decision Rezdiffra first in would an make EMA NASH year, midyear the We treatment available Europe.
are attractive Our future decision preserve for commercialize Europe allows the population Europe us of Europe of in maintain Rezdiffra From than Europe. III increase value to marked our prevalence carcinoma several XXXX NASH-related in opportunity by more established patient expected NASH a increase asset, potentially through is in NASH the a the HCC hepatocellular is in foundational clinical to driving for to a create as Rezdiffra XXX%.
We've in Phase is XXXX, to strategic significant, cases reasons. and of The MAESTRO-NASH trial. therapy platform flexibility NASH growth. an full
with fibrosis positive guidelines. only through And clinical in We approved We III sites European consistent Phase in yet for formed strong EASL to program being relationships disease-specific clinical that guidelines have first-line as was Rezdiffra moderate our favorably the community NASH results is it positioned has note with The trial. despite NASH agent not advanced the This FX/FX in with Europe. with Europe. in and clinical development a affairs our presence Rezdiffra also medical from practice registrational been the team. therapy on-the-ground trial XXX European NASH
the in in build now are starting Rezdiffra XXXX. infrastructure to to Europe We commercialize
they our because aspect strategy patients with life on treat key use compensated X. an Another are to is a times management risk Rezdiffra cirrhosis of liver-related urgency seen of mortality. cirrhosis There with to XX the cycle higher higher is expanding for as patients Slide even at
Rezdiffra evaluates population events patients has this an to NASH opportunity. this our the trial outcomes in that noninvasively compensated An indication cirrhosis. population. It's measures potential in to patient event-driven trial MAESTRO-NASH Our liver patient progression in decompensation double with
conclude on by me summarizing Let Slide progress our X.
in and us enviable being the first sustainable advantage. market giving strong to of have competitive We NASH, position a
this We for in long-term leadership ourselves now globally opportunity, are in leveraging U.S. and expected launch with the fully our Europe. positioning
It's halt XX% starting to a team front with demonstrated that We stiffness out launch of product of It's years. liver-directed profile. launched us, improve ability to an pill. liver in opportunity expert highly blockbuster well-tolerated effective resourced dozens have once-daily, the X the that's we've in an patients or to match medicines. medicine a And has of the desirable
still of than for growth. in XX% more we're biopsies sales as top FX/FX therapy endorsed making EASL a metrics.
Net we launch, have $XX.X not many guidelines progress on all expert the covered, commercial with patients panel Recently line communicated. in with of room recommendations we're on lives drug, targets good X,XXX significant published NASH. in Approximately have prescribed U.S. of virtually Rezdiffra require early million, for and what While XX% first-line more do NITs than accept our
and and educate more clinical pathways work do help care activate change patients. for to to efficient them have practice to to We create physicians
at and patients point in and We adding line are would with tracking launch. in what expect prescribers this right steadily the we
As our are cirrhosis execute Rezdiffra to we trial year. indication with plan opportunity as we expansion to look a as well the forward, on our forward FX/FX outcomes we as look Europe in data we blockbuster on in building patients we NASH, next launch expansion patient medicine expansion untapped to way from and in geographic
accepted proud to supply. is expert reflect I'm my Rezdiffra we've with The We Before filing, Rezdiffra no weeks the and I team. than including and review, company. level, and let turn we case of field label, made very at requirement. priority with team month. importantly ready role best built to built the biopsy launch The approval the was received on months, as We over ship team in progress XX X.
We the accomplished quickly of promoting me we was less a briefly commercial the in out no team FDA I've level an call day a on at approval Mardi, this sufficient required. product the within incredible. a been we've leadership a full received support very what AdCom pretty
plans, seen building is a Rezdiffra all have We've favorable favorable been coverage We physician published. and virtually biopsy. relationships. requiring guidelines strong not Payer
that and We're do. executing we said are to progress. there's more early still on we we would. work making So everything It's
sales. look the a we the forward, are our to for build of strong peak As plans to X/X way the about wire system through our support to aspiration foundation we
to We right more have Rezdiffra. in place even that, and do in the potential significant of strategy confident the we're
So Mardi? with that,
